Cadrenal’s Quiet Expansion Play Is Starting to Get Loud

2 weeks ago

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the…

Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market

2 weeks ago

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread…

NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’

2 weeks ago

New ticker symbol, “FEED” will begin trading on the Nasdaq at the open of the market on December 12, 2025…

Smart Meter and eClinicalWorks More Than Double RPM Adoption in 2025, Powering a New Era of Connected Care for Patients

2 weeks ago

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in Cellular RPM™ and the nation’s most trusted source of patient-generated vital health data,…

BrainCheck Awarded $500K NIH SBIR Phase I Grant to Advance eConsult Platform for Cognitive Care

2 weeks ago

AUSTIN, Texas--(BUSINESS WIRE)--#CognitiveHealth--BrainCheck, the leading FDA Class II digital cognitive assessment and care platform, has been awarded a $500,000 SBIR…

VSee Health, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

2 weeks ago

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE, VSEEW), a leading provider of…

Parexel Named “Best Contract Research Organization” at 21st Annual Scrip Awards

2 weeks ago

Industry leader recognized for excellence and innovation in clinical developmentRALEIGH, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading…

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

2 weeks ago

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability…

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

2 weeks ago

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate…

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

2 weeks ago

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,…